Literature DB >> 28165739

Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (SAM)-Dependent Methyltransferase Family.

Yulan Wang1,2,3, Linjuan Li1,4, Bidong Zhang1,3, Jing Xing1,3, Shijie Chen1,3, Wei Wan1,3, Yakai Song1,5, Hao Jiang1,3, Hualiang Jiang1,3,4, Cheng Luo1,3, Mingyue Zheng1,3.   

Abstract

The disruptor of telomeric silencing 1-like (DOT1L) protein is a histone H3K79 methyltransferase that plays a key role in transcriptional elongation and cell cycle regulation and is required for the development and maintenance of MLL-rearranged mixed lineage leukemia. Much effort has been dedicated toward discovering novel scaffold DOT1L inhibitors using different strategies. Here, we report the development and application of a target-specific scoring function, the SAM score, for (S)-adenosyl-l-methionine (SAM)-dependent methyltransferases, for the discovery of novel DOT1L inhibitors. On the basis of the SAM score, we successfully identified a novel class of DOT1L inhibitors with a scaffold of [1,2,4]-triazolo-[3,4-b][1,3,4]-thiadiazole, in which compound 6 exhibits an IC50 value of 8.3 μM with selectivity versus other tested SAM-dependent methyltransferases. In cellular studies, 6 selectively targets DOT1L, blocks the proliferation of mixed lineage leukemia cell lines, and causes cell cycle arrest and apoptosis. Moreover, we analyzed the putative binding modes of 6 and its analogues obtained by molecular docking, which may assist with the future development of DOT1L inhibitors with improved potency and selectivity profiles.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28165739     DOI: 10.1021/acs.jmedchem.6b01785

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.

Authors:  Manuela Sabatino; Dante Rotili; Alexandros Patsilinakos; Mariantonietta Forgione; Daniela Tomaselli; Fréderic Alby; Paola B Arimondo; Antonello Mai; Rino Ragno
Journal:  J Comput Aided Mol Des       Date:  2018-01-15       Impact factor: 3.686

2.  Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.

Authors:  Garrett S Gibbons; Amarraj Chakraborty; Sierrah M Grigsby; Afoma C Umeano; Chenzhong Liao; Omar Moukha-Chafiq; Vibha Pathak; Bini Mathew; Young-Tae Lee; Yali Dou; Stephan C Schürer; Robert C Reynolds; Timothy S Snowden; Zaneta Nikolovska-Coleska
Journal:  Eur J Med Chem       Date:  2020-01-02       Impact factor: 6.514

3.  Discovery of trisubstituted nicotinonitrile derivatives as novel human GCN5 inhibitors through AlphaScreen-based high throughput screening.

Authors:  Hongru Tao; Jun Wang; Wenchao Lu; Rukang Zhang; Yiqian Xie; Yu-Chih Liu; Rongfeng Liu; Liyan Yue; Kaixian Chen; Hualiang Jiang; Yuanyuan Zhang; Xiaohui Xu; Cheng Luo
Journal:  RSC Adv       Date:  2019-02-08       Impact factor: 4.036

Review 4.  Biological activity of oxadiazole and thiadiazole derivatives.

Authors:  Upare Abhay Atmaram; Selvaraj Mohana Roopan
Journal:  Appl Microbiol Biotechnol       Date:  2022-05-14       Impact factor: 4.813

Review 5.  Protein-Ligand Docking in the Machine-Learning Era.

Authors:  Chao Yang; Eric Anthony Chen; Yingkai Zhang
Journal:  Molecules       Date:  2022-07-18       Impact factor: 4.927

6.  Structural and Energetic Properties of Weak Noncovalent Interactions in Two Closely Related 3,6-Disubstituted-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole Derivatives: In Vitro Cyclooxygenase Activity, Crystallography, and Computational Investigations.

Authors:  Lamya H Al-Wahaibi; Sekar Karthikeyan; Olivier Blacque; Amal A El-Masry; Hanan M Hassan; M Judith Percino; Ali A El-Emam; Subbiah Thamotharan
Journal:  ACS Omega       Date:  2022-09-16

Review 7.  Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.

Authors:  Germana Castelli; Elvira Pelosi; Ugo Testa
Journal:  Onco Targets Ther       Date:  2017-12-28       Impact factor: 4.147

Review 8.  Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.

Authors:  Yan Yi; Shenglei Ge
Journal:  J Hematol Oncol       Date:  2022-03-24       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.